4-[3-(2-nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin

Oncology Research

Volumn 12, Issue 4, 2000, Pages 185-192

  Papadopoulou, Maria V ^a   Ji, Ming ^a   Rao, Mira K ^a   Bloomer, William D ^a  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

Bioreductive drug; Hypoxic cytotoxin; NLCQ 1; Weak DNA intercalation

Indexed keywords

4 (3 (2 NITRO 1 IMIDAZOLYL) PROPYLAMINO) 7 CHLOROQUINOLINE HYDROCHLORIDE; 4-(3-(2-NITRO-1-IMIDAZOLYL)-PROPYLAMINO)-7-CHLOROQUINOLINE HYDROCHLORIDE; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CHLOROQUINE; CYTOTOXIN; IMIDAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL; ANOXIA; ARTICLE; CELL CULTURE; CELL SURVIVAL; CHEMICAL MODEL; CHEMISTRY; DOSE RESPONSE; HUMAN; IC 50; NEOPLASM; RAT; THIN LAYER CHROMATOGRAPHY; TIME;

AMINOQUINOLINES; ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CHLOROQUINE; CHROMATOGRAPHY, THIN LAYER; CYTOTOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; NEOPLASMS; QUINOLINES; RATS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0034577002     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504001108747675     Document Type: Article

References (32)

1. 2 tension measurements. Cancer Res. 51:3316-3322; 1991.
2. 2 tension measurements. Cancer Res. 51:6098-6102; 1991.
3. Hockel, M.; Schlenger, K.; Mitze, M.; Schaffer, U.; Vaupel, P. Hypoxia and radiation response in human tumors. Semin. Radiat. Oncol. 6:3-9; 1996.
4. 2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 26:45-50; 1993.
5. Hughes, C. S.; Shen, J. W.; Subjeck, J. R. Resistance to etoposide induced by three glucose-regulated stresses in Chinese hamster ovary cells. Cancer Res. 49:4452-4454; 1989.
6. Wilson, W. R.; Denny, W. A. DNA-binding nitroheterocycles as hypoxia-selective cytotoxins. In: Dewey, W. C.; Edington, M.; Fry, R. J. M.; Hall, E. J.; Whitmore, G. F., eds. Radiation research: A twentieth-century perspective. New York: Academic Press; 1992:796-801.
7. Denny, W. A.; Wilson, W. R. Bioreducible mustards: A paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev. 12:135-151; 1993.
8. Brown, J. M.; Giaccia, A. J. Tumour hypoxia: The picture has changed in the 1990s. Int. J. Radial. Biol. 65:95-102; 1994.
9. Workman, P.; Stratford, I. J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev. 12:73-82; 1993.
10. Papadopoulou, M. V.; Bloomer, W. D. Nitroheterocyclic-linked acridines as DNA-targeting bioreductive agents. Drugs Future 18(3):231-238; 1993.
11. Roberts, P. B.; Denny, W. A.; Wakelin, L. P. G.; Anderson, R. F.; Wilson, W. R. Radiosensitization of mammalian cells in vitro by nitroacridines. Radiat. Res. 123:153-164; 1990.
12. Cowan, D. S. M.; Panicucci, R.; McClelland, R. A.; Rauth, A. M. Targeting radiosensitizers to DNA by attachment of an intercalating group: Nitroimidazole-linked phenanthridines. Radiat. Res. 127:81-89; 1991.
13. Papadopoulou, M. V.; Rosenzweig, H. S.; Doddi, M.; Bloomer, W. D. 9-[3-(2-Nitro-1-imidazolyl)-propylamino]-1,2,3,4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1. Oncol. Res. 6:439-448; 1994.
14. Papadopoulou, M. V.; Rosenzweig, H. S.; Doddi, D.; Bloomer, W. D. S-THNLA-1 and MeN-THNLA-1. Two new bioreductive agents as radiosensitizers and selective cytotoxins of hypoxic cells. Proceedings of International Conference on Bioreductive Drug Activation, Granlibakken Conference Center, Lake Tahoe, CA, August 16-19, 1994.
15. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. THNLA-1: A DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo. In Vivo 10:49-58; 1996.
16. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. THNLA-1 as radio/ chemosensitizer of EMT-6 tumors in mice. Br. J. Cancer 74(Suppl. XXVII):S267-S270; 1996.
17. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 9-[3-(2-Nitro-1-imidazolyl)-propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer. Oncol. Res. 8:425-434; 1996.
18. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 9-[3-(2-Nitro-1-imidazolyl)-propylamino] cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as chemosensitizer. I. Oncol. Res. 9:249-257; 1997.
19. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. NLCQ-1, a novel hypoxic cytotoxin: Potentiation of melphalan, cisDDP and cyclophosphamide in vivo. Int. J. Radial. Oncol. Biol. Phys. 42:775-779; 1998.
20. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. Potentiation of chemotherapeutic drugs by the bioreductive compound NLCQ-1 against SCCVII tumors in mice. Proc. Am. Assoc. Cancer Res. Annu. Meet. 41:766-767; 2000.
21. Squillace, D. P.; Ruben, S. L.; Reid, J. M.; Ames, M. M. HPLC analysis and murine pharmacokinetics of the cytotoxic bioreductive agent NLCQ-1 (NSC 709257). Proc. Am. Assoc. Cancer Res. Annu. Meet. 41:706; 2000.
22. O'Brien, R. L.; Hahn, F. E. Chloroquine structural requirements for binding to deoxyribonucleic acid and antimalarial activity. Antimicrobial Agents Chemother. 315-320; 1965.
23. Moselen, J. W.; Hay, M. P.; Denny, W. A.; Wilson, W. R. N-[2-(2 - Methyl - 5 - nitroimidazolyl) - ethyl] - 4 - (2 - nitroimidazolyl) butanamide (NSC 639862), a bisnitro-imidazole with enhanced selectivity as a bioreductive drug. Cancer Res. 55:574-580; 1995.
24. Fujita, T.; Iwasa, J.; Hansch, C. A new substituent constant, p, derived from partition coefficients. J. Am. Chem. Soc. 86:5175-5180; 1964.
25. Morgan, A. P.; Lee, J. S.; Pulleyblank, D. E.; Murray, N. L.; Evans, D. H. Review: Ethidium fluorescence assays. Part 1. Physicochemical studies. Nucleic Acids Res. 7:547-569; 1979.
26. Robbie, M. A.; Baguley, B. C; Denny, W. A.; Gavin, J. B.; Wilson, W. R. Mechanism of resistance of noncycling mammalian cells to 4′-(9-acridylamino)methanesulfon-m-anisidine: Comparison of uptake, metabolism, and DNA breakage in log and plateauphase Chinese hamster fibroblast cell cultures. Cancer Res. 48: 310-319; 1988.
27. RN1 reactions. J. Org. Chem. 38:1407-1409; 1973.
28. Bass, G. E.; Hudson, D. R.; Parker, J. E.; Purcell, W. P. Mechanism of antimalarial activity of chloroquine analogs from quantitative structure-activity studies. Free energy related model. J. Med. Chem. 14:275-283; 1971.
29. Robertson, N.; Haigh, A.; Adams, G. E.; Stratford, I. J. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur. J. Cancer 30A: 1013-1019; 1994.
30. Wang, J.; Biedermann, K. A.; Wolf, C. R.; Brown, J. M. Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: Enzymatic studies. Br. J. Cancer 67:321-5; 1993.
31. Walton, M. I.; Workman, P. Nitroimidazole bioreductive metabolism: Quantitation and characterization of mouse tissue benzidazole nitroreductase in vivo and in vitro. Biochem. Pharmacol. 36: 887-896; 1987.
32. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1). A novel bioreductive agent with enhanced hypoxic selectivity. Proceedings of 45th Annual Meeting of the Radiation Research Society and 16th Annual Meeting of the North American Hyperthermia Society, Providence, RI, May 3-7, 1997.